The RA3-6B2 antibody reacts with the human and mouse CD45 isoform known as CD45R, or B220, a protein tyrosine phosphatase of 220 kDa. CD45 is one of the most abundant hematopoietic markers, and is expressed on all leukocytes (the Leukocyte Common Antigen, LCA). Various isoforms are generated and expressed in cell-specific patterns, all critical for leukocyte function. In mouse, the CD45R/B220 isoform is predominantly found on B cells, at varying levels on all stages from pro-B cells to activated B cells, and may also be detected on certain T cell and NK cell subsets. It is of note that B220 is not similarly expressed on human B cells, where it appears to be differentiation-specific and therefore expressed on only some B cell subsets. Other forms of CD45 with restricted cellular expression include CD45RA, CD45RB, CD45RO and several others.
The RA3-6B2 antibody is one of the most consistently used leukocyte markers for B cells, T cell subsets and NK cell subsets in human and mouse. This antibody has also been reported as cross-reactive with feline CD45R/B220.
Willinger T and Flavell RA. 2012. Proc. Natl. Acad. Sci. 109:8670-8675. (Flow cytometry)
Meredith MM, Liu K, Darrasse-Jeze G, Kamphorst AO, Schreiber HA, Guermonprez P, Idoyaga J, Cheong C, Yao K-H, Niec RE, and Nussenzweig MC. 2012. J. Exp. Med. 209: 1153-1165. (Immunofluorescence microscopy: acetone-fixed frozen tissue)
Becker-Herman A, Meyer-Bahlburg A, Schwartz MA, Jackson SW, Hudkins KL, Liu C, Sather BD, Khim S, Liggitt D, Song W, Silverman GJ, Alpers CE and Rawlings DJ. 2011. J. Exp. Med. 208:2033-2042. (Immunofluorescence microscopy - OCT embedded frozen tissue)
Bertossi A, Aichinger M, Sansonetti P, Lech , Neff F, Pal M, Wunderlich FT, Anders H, Klein L, and Schmidt-Supprian M. 2011. J. Exp. Med. 208:1749-1756. (Immunofluorescence microscopy)
De Clercq S, Gembarska A, Denecker G, Maetens M, Naessens M, Haigh K, Haigh JJ, and Marine J-C. 2010. Mol. Cell. Biol. 30:5394-5405. (Western Blot)
Nutt SL, Metcalf D, D"™Amico A, Polli M, and Wu L. 2005. J. Exp. Med. 201:221-231. (Immunomagnetic bead depletion)
Cappione AJ, Pugh-Bernard AE, Anolik JH, and Sanz I. 2004. J. Immunol. 172: 4298-4307. (Immunoprecipitation)
Monteith CE, Chelack BJ, Davis WC, and Haines DM. 1996. Can. J. Vet. Res. 60(3): 193-198. (Immunohistochemistry - feline tissue)
Whiteland JL, Nicholls SM, Shimeld C, Easty DL, Williams NA, and Hill TJ. 1995. J. Histochem. Cytochem. 43:313-320. (Immunohistochemistry - frozen tissue, paraffin embedded tissue)
Domiati-Saad R, Ogle EW, and Justement LB. 1993. J. Immunol. 151: 5936-5947. (in vivo blocking)
Aviva Systems Biology为我们的客户提供了大量用于研究和诊断应用的高质量抗体。英杰华目前提供针对7,000多种不同蛋白质靶标的抗体,这是因为我们的高通量抗体生产每月会释放200多种新抗体。Aviva的重点是针对转录,表观遗传学和细胞信号传导领域关键靶标的抗体。Aviva的抗体库包含针对许多目标的独特抗体含量,这些目标是其他地方无法买到的。我们将重点放在面向家庭的抗体生产上,从而产生了针对大多数关键蛋白质家族成员的抗体,例如转录因子,转录调节剂,RNA结合蛋白,离子通道和细胞膜靶蛋白。
英杰华(Aviva)还拥有大量额外的17,000种抗体,这些抗体目前正在使用6个组织和6个细胞系进行全面的蛋白质印迹表征和验证。随着英杰华高通量处理团队对这些候选新产品的描述,我们预计明年将发布数千种新抗体产品。
英杰华欢迎客户提出建议,并鼓励研究人员通过info@avivasysbio.com与我们联系,以寻求满足其研究要求的特定抗体。如果我们有满足您需求的抗体,但尚未发布,我们将齐心协力使您的目标在队列中前进,并在发布新抗体时提醒您有可用的新抗体。